Pilot shows smartphone app and population management-facilitated Type-2 diabetes management can significantly improve blood glucose control
Recent results on the effectiveness of Glooko-enabled Patient Remote Monitoring and Diabetes Self-Management Presented on October 22, 2015 at the Diabetes Technology Meeting
Thursday, Oct 29, 2015 – Palo Alto, CA – Glooko, the leading unified platform for diabetes management, today announced that Glooko was featured in a poster presentation on the effectiveness of Glooko-enabled Type 2 diabetes management resulting from a pilot conducted at the Diabetes & Glandular Disease (DGD) Clinic. Based in San Antonio, Texas, DGD is the one of the largest Type 2 adult endocrinology facilities in the country. The presentation, given by Dr. Jerome Fischer, a partner and Endocrinologist at DGD, occurred during the scientific poster session at the Diabetes Technology Meeting on October 23, 2015 in Bethesda, MD.
The twelve-week pilot measured the effectiveness of using Glooko, which enables data-driven clinical interactions between clinician and patient via the Glooko mobile app and Glooko Population Tracker, to facilitate remote monitoring and coaching of Type 2 patients by nurse practitioners at DGD (intervention group). The intervention group was compared with a control group in which Type 2 patients used Glooko alone for diabetes self management (along with treatment as usual).
Both the intervention and control groups experienced a statistically significant improvement in mean blood glucose and glycemic variability. Notably, subjects who experienced three or more Glooko-facilitated remote clinical interactions with a nurse practitioner experienced a significantly better improvement in mean blood glucose compared to control subjects.
In a post-pilot survey, 96% of responding subjects said Glooko made it easier to adhere to their diabetes therapy regimen. In addition, 81% of responding subjects reported receiving therapy recommendations during their remote clinical interactions; these interactions regularly included insulin and medication adjustments. “Improving the quality, frequency and cost of clinical interactions between the clinician and patient is crucial for optimizing diabetes management,” said Rick Altinger, Glooko CEO. For information on pilot results or a copy of the poster presentation, contact email@example.com.
Glooko is the Unified Platform for Diabetes Management and provides an FDA-cleared, HIPAA-compliant Web and Mobile application for diabetes patients and clinicians which improves outcomes and lowers costs. The platform seamlessly unifies data from over 50 of the leading blood glucose meters, insulin pumps, continuous glucose monitors, activity trackers and biometric devices to deliver insights that improve personal and clinical decision support. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and pattern-triggered notifications to patients, health systems and payers. The Glooko platform also allows customers and third party developers to create branded modules for Glooko users. Learn more at http://www.glooko.com and follow us at Twitter.com/GlookoInc , and Facebook.com/Glooko .